Phathom Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Phathom Pharmaceuticals's estimated annual revenue is currently $14.9M per year.
- Phathom Pharmaceuticals's estimated revenue per employee is $33,067
- Phathom Pharmaceuticals's total funding is $90M.
- Phathom Pharmaceuticals's current valuation is $479.7M. (January 2022)
Employee Data
- Phathom Pharmaceuticals has 450 Employees.
- Phathom Pharmaceuticals grew their employee count by 200% last year.
Phathom Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | CEO and President | Reveal Email/Phone |
3 | Head Information Technology | Reveal Email/Phone |
4 | VP Sales | Reveal Email/Phone |
5 | VP, Financial Planning & Analysis | Reveal Email/Phone |
6 | VP, Regulatory CMC and Clinical Supplies | Reveal Email/Phone |
7 | VP, Head Development Operations | Reveal Email/Phone |
8 | General Counsel | Reveal Email/Phone |
9 | General Counsel and Secretary | Reveal Email/Phone |
10 | VP, Head Market Access | Reveal Email/Phone |
Phathom Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Phathom Pharmaceuticals?
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders. We have created a nimble, entrepreneurial environment that fosters the spirit of collective ownership, accountability, proprietorship and achievement ￃﾢ￢ﾂﾬ￢ﾀﾝ elements that are key to our success.
keywords:N/A
$90M
Total Funding
450
Number of Employees
$14.9M
Revenue (est)
200%
Employee Growth %
$479.7M
Valuation
N/A
Accelerator
Phathom Pharmaceuticals News
At the Needham Healthcare Conference, Phathom Pharmaceuticals Inc. PHAT-0.61%+ Free Alerts. says that licensor Takeda Pharmaceutical Co Ltd.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal...
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal...
Phathom Pharmaceuticals, Inc. reported it has obtained a $200 million term loan facility from Hercules Capital, Inc., a leader in customized debt financing for companies in life sciences and technology-related markets. This additional capital further strengthens Phathoms balance sheet in advanc ...
FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported it has obtained a $200 million term loan f ...
Other Companies in Florham Park
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $95.1M | 473 | 2% | N/A |
#2 | $119.4M | 594 | 3% | N/A |
#3 | $200M | 653 | 1% | N/A |
#4 | $163.5M | 730 | 8% | N/A |
#5 | $423.4M | 1205 | -2% | N/A |